Your browser is no longer supported. Please, upgrade your browser.
BMRN BioMarin Pharmaceutical Inc. monthly Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own0.40% Shs Outstand161.09M Perf Week1.46%
Market Cap21.09B Forward P/E- EPS next Y-1.67 Insider Trans-33.99% Shs Float160.84M Perf Month-9.31%
Income-211.80M PEG- EPS next Q-0.65 Inst Own99.80% Short Float3.18% Perf Quarter4.24%
Sales861.50M P/S24.47 EPS this Y28.10% Inst Trans0.73% Short Ratio3.87 Perf Half Y22.25%
Book/sh14.69 P/B8.91 EPS next Y28.30% ROA-6.90% Target Price161.65 Perf Year84.87%
Cash/sh4.23 P/C30.93 EPS next 5Y25.00% ROE-10.80% 52W Range65.91 - 151.75 Perf YTD44.79%
Dividend- P/FCF- EPS past 5Y37.13% ROI-4.70% 52W High-13.75% Beta0.65
Dividend %- Quick Ratio2.80 Sales past 5Y18.30% Gross Margin82.80% 52W Low98.59% ATR5.75
Employees1681 Current Ratio3.50 Sales Q/Q30.60% Oper. Margin-28.50% RSI (14)45.47 Volatility5.51% 4.23%
OptionableYes Debt/Eq0.28 EPS Q/Q-121.70% Profit Margin-24.60% Rel Volume0.81 Prev Close128.10
ShortableYes LT Debt/Eq0.28 EarningsAug 03 AMC Payout- Avg Volume1.32M Price130.89
Recom1.90 SMA20-3.46% SMA50-5.68% SMA20013.51% Volume1,070,125 Change2.18%
Jul-08-15Reiterated RBC Capital Mkts Outperform $145 → $155
Jun-19-15Downgrade Robert W. Baird Outperform → Neutral $125 → $133
Jun-18-15Reiterated Sun Trust Rbsn Humphrey Buy $151 → $170
Jun-18-15Reiterated RBC Capital Mkts Outperform $125 → $145
Jun-18-15Reiterated Piper Jaffray Overweight $123 → $147
Jun-18-15Reiterated Jefferies Buy $135 → $150
Jun-18-15Reiterated Deutsche Bank Buy $140 → $156
Jun-18-15Reiterated Canaccord Genuity Buy $115 → $150
Jun-05-15Initiated Barclays Overweight $150
May-27-15Reiterated JP Morgan Overweight $125 → $140
May-01-15Reiterated JP Morgan Overweight $120 → $125
Mar-27-15Reiterated UBS Buy $112 → $136
Mar-27-15Reiterated Deutsche Bank Buy $90 → $140
Dec-19-14Reiterated RBC Capital Mkts Outperform $103 → $110
Dec-11-14Reiterated UBS Buy $87 → $112
Nov-25-14Reiterated RBC Capital Mkts Outperform $87 → $103
Oct-24-14Reiterated RBC Capital Mkts Outperform $77 → $87
Feb-19-14Reiterated Barclays Equal Weight $73 → $76
Jan-14-14Reiterated Deutsche Bank Buy $75 → $85
Jan-10-14Downgrade Barclays Overweight → Equal Weight $75 → $73
Aug-27-15 12:45PM  Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews at TheStreet
12:00PM  The Duchenne Muscular Dystrophy Race Is On at Motley Fool
09:30AM  The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure
Aug-26-15 04:30PM  Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review +5.75%
10:41AM  Sarepta Upgraded On Promising Muscular-Dystrophy Drug at Investor's Business Daily
08:55AM  Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data
Aug-25-15 06:57PM  Sarepta gains after-hours as FDA accepts application for Duchenne drug approval at bizjournals.com
05:00PM  Medivation to Gain Global Rights to BioMarin's Talazoparib
12:54PM  BioMarin's Medivation Deal Boosts EPS at Barrons.com
12:20AM  Two Bay Area drug companies cut half-billion-dollar cancer drug deal at bizjournals.com
Aug-24-15 10:22AM  Medivation Buying Breast-Cancer Drug From BioMarin at Investor's Business Daily -5.14%
07:12AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure,
07:00AM  Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin Marketwired
07:00AM  Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin GlobeNewswire
Aug-22-15 08:41AM  BioMarin's Big Bet on Muscular Dystrophy Is Already Paying Off at Motley Fool
Aug-21-15 09:41AM  UBS Analysts Might've Found Another BioMarin Catalyst
08:21AM  3 Biotech Stocks That Could Be Buyout Targets at Motley Fool
Aug-20-15 02:50PM  BioMarin's Drisapersen Gets Rare Pediatric Disease Status
01:51PM  IBB and XBI Underperformed the Benchmark Indexes
Aug-19-15 04:05PM  BioMarin Receives Rare Pediatric Disease Designation From FDA for Drisapersen for the Potential Treatment of Duchenne Muscular Dystrophy GlobeNewswire
10:37AM  Forbes Ranks BioMarin 10th Most Innovative Company in the World GlobeNewswire
Aug-18-15 09:56AM  IBB Fell by 3.62% in the Week Ending August 7
Aug-17-15 08:02AM  Are the 3 Best-Performing Big-Cap Biotech Stocks of 2015 Still Worth Buying? at Motley Fool
Aug-15-15 03:07PM  The 5 Most Expensive Drugs in the World in 2015 at Motley Fool
Aug-11-15 01:05PM  BIOMARIN PHARMACEUTICAL INC Financials
Aug-09-15 11:01AM  5 Trade Ideas for Monday: Rockwell Collins, BioMarin, Tractor Supply, Progressive & American Electric Power
Aug-08-15 08:10PM  10-Q for BioMarin Pharmaceutical, Inc. at Company Spotlight
Aug-07-15 05:58PM  Sarepta Posts Narrower-than-Expected Loss in Q2, Shares Up - Analyst Blog
Aug-06-15 09:15AM  Cowen Raises Price Targets on Focus Call Stocks to Buy at 24/7 Wall St. -6.21%
Aug-05-15 06:17AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report
Aug-04-15 02:56PM  BioMarin Q2 Loss Narrower than Expected, Maintains Outlook - Analyst Blog
11:25AM  Seven Reasons to Love Biomarin's Duchenne Drug Falls One Short at TheStreet
07:08AM  BioMarin Pharmaceutical (BMRN) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
03:20AM  Edited Transcript of BMRN earnings conference call or presentation 3-Aug-15 8:30pm GMT
Aug-03-15 09:00PM  BioMarin Pharmaceuticals: Lumpy Sales Strike Again at Motley Fool
05:15PM  Biomarin falls on earnings
04:30PM  Biomarin Pharmaceutical Inc Earnings Call scheduled for 4:30 pm ET today
04:20PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:12PM  BioMarin reports 2Q loss
04:02PM  BioMarin Announces Second Quarter 2015 Financial Results and Company Update GlobeNewswire
10:40AM  3 Biotech Stocks to Buy With Huge Catalysts Coming Soon at 24/7 Wall St.
07:07AM  Q2 2015 Biomarin Pharmaceutical Inc Earnings Release - After Market Close
Jul-31-15 02:20PM  Will BioMarin Top Q2 Earnings Again on Vimizim Sales? - Analyst Blog
Jul-30-15 11:07AM  Biogens Hemophilia Portfolio: Growing Market Share in 2Q15
08:48AM  Why BioMarin Pharmaceutical (BMRN) Might Surprise This Earnings Season - Tale of the Tape
Jul-29-15 02:10PM  Here are all the Boston-area biotechs about to buy or get bought at bizjournals.com
Jul-27-15 08:00AM  BioMarin Joins the NASDAQ-100 Index GlobeNewswire
Jul-26-15 10:57AM  5 Trade Ideas for Monday: Agrium, BioMarin, Hain Celestial, Landstar & Nasdaq OMX
Jul-21-15 06:31PM  BioMarin Provides Update on Phase II Talazoparib Study - Analyst Blog
Jul-20-15 03:22PM  This Orphan Drugmaker Deserves a Spot on Your Radar at Motley Fool
02:10PM  FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs at TheStreet
08:50AM  4 Large Cap Biotech Stocks to Buy Before Earnings at 24/7 Wall St.
08:30AM  BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer GlobeNewswire
Jul-15-15 08:30AM  BioMarin to Host Second Quarter 2015 Financial Results Conference Call and Webcast on Monday, August 3 at 4:30pm ET GlobeNewswire
Jul-13-15 09:54AM  Short Sellers Shy Away From Biotech Stocks
Jul-10-15 12:00PM  BioMarin Pharmaceutical (BMRN) Stock is the Chart of the Day at TheStreet
Jul-08-15 12:12PM  BioMarin Gets Price Target Hike On Pipeline Strength at Investor's Business Daily
09:21AM  BioMarin Pharmaceutical (BMRN) Stock Price Target Increased by Analysts at TheStreet
Jul-02-15 03:45PM  Dwarfism Drug Brings Mixed Emotions for Little People, Parents at Bloomberg
03:45PM  Dwarfism Drug Brings Mixed Emotions for Little People, Parents
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta - Press Releases
Jul-01-15 11:29AM  Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress - Analyst Blog
Jun-30-15 05:57PM  Should The Biotech Bubble Be Feared?
04:30PM  Sarepta Files Eteplirsen NDA, Secures $40M Debt Financing - Analyst Blog
04:25PM  BioMarin's NDA for DMD Drug Drisapersen Accepted by FDA - Analyst Blog
Jun-29-15 03:50PM  Sarepta CEO: Teamwork has been key to quick progress on Duchenne drug at bizjournals.com
10:18AM  BioMarin, Sarepta Muscular Dystrophy Drugs Progress at Investor's Business Daily
08:30AM  BioMarin Announces FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping GlobeNewswire
07:02AM  Sarepta Submits DMD Drug for FDA Approval Review at TheStreet
Jun-26-15 06:35PM  BioMarin DMD Drug Drisapersen Validated for EU Review - Analyst Blog
Jun-25-15 04:01PM  BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping GlobeNewswire
09:30AM  The Zacks Analyst Blog Highlights: BioMarin, Vical, Epizyme, Amgen and Medicines Co - Press Releases
Jun-24-15 08:44AM  Biotech Stock Roundup: BioMarin Jumps on Dwarfism Data, Vical Plunges on Vaccine Data - Analyst Blog
Jun-23-15 03:24PM  BioMarin CEO: Excited about dwarfism drug potential
06:00AM  5 Biotech Stocks to Trade for Gains at TheStreet
Jun-22-15 12:02PM  BioMarin Pharmaceutical (BMRN) Stock Is the 'Chart of the Day' at TheStreet
Jun-20-15 12:19AM  Charting the Market at Barrons.com
Jun-19-15 04:10PM  BioMarin Pharmaceutical Surges on Price Target Increase - Analyst Blog
03:19PM  Biotech to break out, buy these names: Analyst at CNBC
02:29PM  BioMarin: Too Expensive? at Barrons.com
01:41PM  Biotechs about to break out: Pro
08:50AM  Top Analyst Upgrades and Downgrades: BioMarin, BP, Micron, Vonage, Finisar, ConEd, Red Hat and More at 24/7 Wall St.
06:52AM  Biomarin Pharm downgraded by Robert W. Baird
Jun-18-15 07:35PM  Cramer Remix-Before strolling with Johnnie Walker at CNBC +12.18%
04:21PM  Daily Movers: Welcoming Fitbit; BioMarin Soars Again, While Oracle Slumps
03:32PM  Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following Announcement Of Positive BMN 111 Data; Jabil Circuit Shares Fall
02:55PM  Edited Transcript of BMRN conference call or presentation 17-Jun-15 8:30pm GMT
01:40PM  3 Drivers Supporting BioMarin
01:31PM  Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius Health Shares Surge
12:08PM  BioMarin Pharmaceutical Inc. (BMRN) Surges But Is It A Good Stock To Buy Now? at Insider Monkey
11:22AM  BioMarin (BRMN) Stock Jumps on Dwarfism Treatment Trial at TheStreet
10:36AM  BioMarin Stock Hits High On Dwarfism Drug Success at Investor's Business Daily
10:31AM  BioMarin's Results Are In: What Do They Mean?
10:29AM  Jim Cramer -- BioMarin and Radius Health Deserve Today's Big Rally at TheStreet
10:22AM  Mid-Morning Market Update: Markets Open Higher; Kroger Earnings Beat Views
10:11AM  BioMarin Spikes on Drug Trial; Shares Hit New High at Barrons.com
09:27AM  Cramer's Mad Dash: BMRN & RDUS
08:55AM  Well soon find out if this gold rally is for real at MarketWatch
07:22AM  Study for treatment for dwarfism send BioMarin stock skyward
Jun-17-15 05:39PM  Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours Movers
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; talazoparib, an orally available poly-ADP ribose polymerase inhibitor for cancer treatment; BMN 111, a peptide therapeutic for achondroplasia treatment; BMN 044, BMN 045, and BMN 053 for DMD treatment; and cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as BMN 270 and BMN 250. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. S.A. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerAug 12Sale134.721,500202,08328,758Aug 13 10:40 AM
Ajer Jeffrey RobertSVP, Chief Commercial OfJul 20Option Exercise63.103,000189,30038,605Jul 22 03:21 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJul 20Sale150.003,000450,00035,605Jul 22 03:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 07Sale139.071,500208,60030,258Jul 09 05:06 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 05Sale122.301,649201,66928,229Jun 08 06:09 PM
FUCHS HENRY JEVP, Chief Medical OfficerJun 05Sale122.321,864228,00172,846Jun 08 06:06 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 04Sale122.351,362166,64635,605Jun 08 05:43 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 01Sale123.7637746,65738,455Jun 03 08:23 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 01Sale124.163,945489,81131,679Jun 03 08:27 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 29Sale126.151,578199,06535,624Jun 03 08:27 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 26Sale126.551,625205,64739,245May 26 07:52 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 18Sale124.781,864232,58476,746May 19 07:21 PM
Davis George EricSVP, General CounselMay 18Sale125.262,558320,41569,226May 19 07:18 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 18Sale130.0034,0784,430,14041,507May 28 05:10 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 13Sale121.371,434174,03880,646May 14 06:54 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 11Sale121.642,869348,98883,646May 12 07:27 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 06Option Exercise33.9333,6311,141,21576,664May 08 05:49 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 06Sale119.1434,0194,053,04242,645May 08 05:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Option Exercise6.4623,218149,98856,476May 05 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Sale114.9823,2182,669,51733,258May 05 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Sale114.983,505402,992248,654May 05 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Option Exercise6.4622,546145,64755,804Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Sale120.5322,5462,717,54633,258Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Sale120.533,506422,590251,251Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 20Sale126.401,000126,39633,258Mar 24 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 17Sale124.871,000124,86634,258Mar 18 08:02 PM
FUCHS HENRY JEVP, Chief Medical OfficerMar 16Option Exercise21.5140,000860,400129,950Mar 18 07:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Sale123.481,000123,47735,258Mar 18 08:02 PM
FUCHS HENRY JEVP, Chief Medical OfficerMar 16Sale123.5741,3155,105,16688,635Mar 18 07:50 PM
Davis George EricSVP, General CounselMar 13Option Exercise37.0815,000556,23988,846Mar 17 06:03 PM
Davis George EricSVP, General CounselMar 13Sale120.8715,0001,813,00273,846Mar 17 06:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Sale114.892,021232,20136,258Mar 11 06:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Option Exercise12.9915,000194,85057,279Mar 11 06:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Sale112.1319,0002,130,38338,279Mar 11 06:32 PM
BAFFI ROBERTEVP, Technical OperationsMar 05Option Exercise17.1114,051240,364123,751Mar 05 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 05Option Exercise12.9910,000129,90052,279Mar 05 08:20 PM
BAFFI ROBERTEVP, Technical OperationsMar 05Sale116.3714,0511,635,091109,700Mar 05 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 05Sale113.7010,0001,137,01642,279Mar 05 08:20 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 04Option Exercise9.865004,93043,695Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 04Sale107.7191698,66042,279Mar 04 07:39 PM
LAPALME PIERREDirectorMar 03Option Exercise14.2420,000284,80050,150Mar 05 05:34 PM
Mueller BrianVP, Corporate ControllerMar 03Option Exercise28.237,000197,61015,800Mar 05 05:31 PM
Mueller BrianVP, Corporate ControllerMar 03Sale109.467,000766,2108,800Mar 05 05:31 PM
LAPALME PIERREDirectorMar 03Sale106.5720,0002,131,40030,150Mar 05 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 03Sale107.425,000537,097215,157Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Option Exercise12.993,00038,97046,195Mar 04 07:39 PM
Davis George EricSVP, General CounselMar 02Option Exercise26.4923,000609,27087,246Mar 04 07:41 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Option Exercise39.0615,500605,43084,176Mar 04 07:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Sale107.0015,5001,658,50068,676Mar 04 07:48 PM
Davis George EricSVP, General CounselMar 02Sale108.3123,0002,491,02764,246Mar 04 07:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Sale107.963,000323,89343,195Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Sale108.445,000542,195220,157Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 09Sale94.142,000188,286225,157Jan 13 07:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Option Exercise12.993,00038,97046,195Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale88.733,000266,19343,195Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale88.732,000177,462227,157Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Option Exercise12.992,00025,98045,195Dec 12 01:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Sale95.002,000190,00043,195Dec 12 01:51 PM
LEWIS ALANDirectorDec 04Option Exercise21.517,500161,32528,900Dec 08 06:50 PM
LEWIS ALANDirectorDec 04Sale89.907,500674,22521,400Dec 08 06:50 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Option Exercise38.5912,000463,08043,590Dec 05 05:26 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Sale91.0112,0001,092,16131,590Dec 05 05:26 PM
Mueller BrianVP, Corporate ControllerDec 02Option Exercise28.235,000141,1509,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 02Sale91.825,000459,1004,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Option Exercise20.986,950145,78511,543Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Sale90.256,950627,2384,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerNov 26Sale88.973,400302,5084,593Dec 02 05:19 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Option Exercise12.992,00025,98045,195Nov 28 09:24 PM
Davis George EricSVP, General CounselNov 25Option Exercise26.4920,000529,80084,426Nov 28 09:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Sale90.002,000180,00043,195Nov 28 09:24 PM
Davis George EricSVP, General CounselNov 25Sale89.7520,0001,795,00064,426Nov 28 09:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 12Sale81.511,00081,513228,157Nov 14 02:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Option Exercise12.994,00051,96047,195Nov 12 07:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Option Exercise21.5120,000430,20096,550Nov 12 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Sale87.004,000348,00043,195Nov 12 07:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Sale86.5520,0001,730,98276,550Nov 12 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 03Sale85.333,000256,00243,195Nov 05 07:45 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 03Sale83.54473,92631,590Nov 05 07:44 PM
BAFFI ROBERTEVP, Technical OperationsOct 30Option Exercise38.5929,9631,156,272129,163Oct 31 02:58 PM
Davis George EricSVP, General CounselOct 30Option Exercise26.4915,000397,35079,426Nov 03 07:21 PM
Davis George EricSVP, General CounselOct 30Sale83.2015,0001,247,93064,426Nov 03 07:21 PM
BAFFI ROBERTEVP, Technical OperationsOct 29Option Exercise33.7445,4621,533,721144,662Oct 31 02:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Option Exercise12.992,00025,98048,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Sale80.002,000160,00046,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Option Exercise12.992,00025,98048,195Oct 23 06:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Sale75.002,000150,00046,195Oct 23 06:34 PM
Davis George EricSVP, General CounselSep 19Option Exercise21.5117,536377,19981,962Sep 23 08:41 PM
Davis George EricSVP, General CounselSep 19Sale69.7517,5361,223,13664,426Sep 23 08:41 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 03Sale69.77181,25668,733Feb 10 12:57 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Option Exercise39.0616,000624,96084,676Sep 03 06:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Sale69.8316,0001,117,31468,676Sep 03 06:48 PM